These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32169314)

  • 21. Reply to Yi Zhou, Weigang Yan, and Hanzhong Li's Letter to the Editor re: Eduard Baco, Erik Rud, Lars Magne Eri, et al. A Randomized Controlled Trial to Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. Eur Urol 2016;69:149-56.
    Baco E; Rud E; Vlatkovic L
    Eur Urol; 2016 Aug; 70(2):e55. PubMed ID: 26852076
    [No Abstract]   [Full Text] [Related]  

  • 22. Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
    Arends TJH; Witjes JA
    Eur Urol; 2019 Feb; 75(2):e26. PubMed ID: 30268661
    [No Abstract]   [Full Text] [Related]  

  • 23. Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82.
    Glicksman RM; Berlin A
    Eur Urol; 2021 Sep; 80(3):e79-e80. PubMed ID: 34158186
    [No Abstract]   [Full Text] [Related]  

  • 24. Reply to Sławomir Poletajew, Piotr Radziszewski, Juan Palou's Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
    Arends TJ; Witjes JA
    Eur Urol; 2017 Jan; 71(1):e31-e32. PubMed ID: 27425383
    [No Abstract]   [Full Text] [Related]  

  • 25. Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer?
    Vila-Reyes H; DeCastro GJ; McKiernan JM
    Eur Urol; 2021 Jan; 79(1):e35-e36. PubMed ID: 32829975
    [No Abstract]   [Full Text] [Related]  

  • 26. Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636-43.
    Bandini M; Necchi A
    Eur Urol; 2020 Jun; 77(6):e159-e160. PubMed ID: 32184002
    [No Abstract]   [Full Text] [Related]  

  • 27. Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Carvalho FLF; Mossanen M; Van Allen EM; Mouw KW
    Eur Urol; 2022 Nov; 82(5):e141-e142. PubMed ID: 35945087
    [No Abstract]   [Full Text] [Related]  

  • 28. Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li's Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3-5.
    Capitanio U; Bedke J; Albiges L; Volpe A; Giles RH; Hora M; Marconi L; Klatte T; Abu-Ghanem Y; Dabestani S; Fernández Pello S; Hofmann F; Kuusk T; Campi R; Tahbaz R; Powles T; Ljungberg B; Bex A
    Eur Urol; 2023 Mar; 83(3):e74-e75. PubMed ID: 36526491
    [No Abstract]   [Full Text] [Related]  

  • 29. Reply to Wei He, Shuxiong Zeng, and Chuanliang Xu's Letter to the Editor re: Riccardo Mastroianni, Gabriele Tuderti, Mariaconsiglia Ferriero, et al. Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial. Eur Urol 2024;85:422-30.
    Mastroianni R; Chiacchio G; Simone G
    Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38880713
    [No Abstract]   [Full Text] [Related]  

  • 30. Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?
    Powles T; Gómez de Liaño A; Ackerman C
    Eur Urol; 2017 Nov; 72(5):e137-e138. PubMed ID: 28606457
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply to Donald L. Lamm and Nilay M. Gandhi's letter to the editor re: Behfar Ehdaie, Richard Sylvester, Harry W. Herr. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579-85.
    Ehdaie B; Sylvester R; Herr HW
    Eur Urol; 2014 Jan; 65(1):e7. PubMed ID: 24113320
    [No Abstract]   [Full Text] [Related]  

  • 32. Reply to Santhanam Sundar's letter to the editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18.
    Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA; Lebret T
    Eur Urol; 2012 Aug; 62(2):e45-6. PubMed ID: 22579356
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534.
    Sung WW
    Eur Urol Oncol; 2024 Feb; 7(1):163. PubMed ID: 37679244
    [No Abstract]   [Full Text] [Related]  

  • 34. Reply to Bernhard Liedl, Klaus Goeschen, and Florian Wagenlehner's Letter to the Editor re: Benoit Peyronnet, Emma Mironska, Christopher Chapple, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol 2019, 75:988-1000.
    Peyronnet B; Chapple C; Cornu JN
    Eur Urol; 2019 Oct; 76(4):e107-e108. PubMed ID: 31326217
    [No Abstract]   [Full Text] [Related]  

  • 35. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
    Hussain SA; Porta N; Hall E; Salawu A; Lewis R; Sreenivasan T; Wallace J; Crundwell M; Jenkins P; Tremlett J; Huddart R; James ND;
    Eur Urol; 2021 Feb; 79(2):307-315. PubMed ID: 33293079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80:e100.
    Dev S
    Eur Urol; 2022 Jan; 81(1):e25. PubMed ID: 34663524
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation.
    Safiri S; Ayubi E
    Eur Urol; 2017 Sep; 72(3):e63. PubMed ID: 28648368
    [No Abstract]   [Full Text] [Related]  

  • 38. Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
    Rouprêt M
    Eur Urol; 2016 Mar; 69(3):e51-2. PubMed ID: 26461109
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid 2022;1:EVIDoa2200092.
    Sussman J; Konety B; Ahmadi H
    Eur Urol; 2024 Feb; 85(2):178-179. PubMed ID: 37580211
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply to Peng He, Xiaohui Wang, and Hao Li's Letter to the Editor re: Yu Xiao, Kaiyu Qian, Yongwen Luo, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Renal Failure Patients: A Potential Covert Source of Infection. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03.025.
    Xiao Y; Qian K; Luo Y; Chen S; Lu M; Wang G; Ju L; Wang X
    Eur Urol; 2020 Nov; 78(5):e203-e204. PubMed ID: 32405138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.